Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007 Mar;298(10):469-77.
doi: 10.1007/s00403-006-0726-5.

Serologic and immunohistochemical prognostic biomarkers of cutaneous malignancies

Jochen Utikal  1 , Dirk Schadendorf, Selma Ugurel
Affiliations
Review

Serologic and immunohistochemical prognostic biomarkers of cutaneous malignancies

Jochen Utikal et al. Arch Dermatol Res. 2007 Mar.

Abstract

Biomarkers are important tools in clinical diagnosis and prognostic classification of various cutaneous malignancies. Besides clinical and histopathological aspects (e.g. anatomic site and type of the primary tumour, tumour size and invasion depth, ulceration, vascular invasion), an increasing variety of molecular markers have been identified, providing the possibility of a more detailed diagnostic and prognostic subgrouping of tumour entities, up to even changing existing classification systems. Recently published gene expression or proteomic profiling data relate to new marker molecules involved in skin cancer pathogenesis, which may, after validation by suitable studies, represent future prognostic or predictive biomarkers in cutaneous malignancies. We, here, give an overview on currently known serologic and newer immunohistochemical biomarker molecules in the most common cutaneous malignancies, malignant melanoma, squamous cell carcinoma and cutaneous lymphoma, particularly emphasizing their prognostic and predictive significance.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Schematic presentation of the cellular localization and function of the melanoma biomarkers S100-beta, tyrosinase and melanoma inhibitory activity (MIA)
Fig. 2
Fig. 2
Kaplan–Meier survival curves of 65 patients with advanced metastatic melanoma (AJCC stage IV). Patients with elevated serum levels of S100-beta show a significantly reduced survival probability compared to patients with normal S100-beta serum concentrations (P = 0.003 by log rank test; detection system LIAISON Sangtec 100)
See this image and copyright information in PMC

References

    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1046/j.1365-2133.2002.04691.x', 'is_inner': False, 'url': 'https://doi.org/10.1046/j.1365-2133.2002.04691.x'}, {'type': 'PubMed', 'value': '12000380', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/12000380/'}]}
    2. Acland K, Evans AV, Abraha H, Healy CM, Roblin P, Calonje E, Orchard G, Higgins E, Sherwood R, Russell-Jones R (2002) Serum S100 concentrations are not useful in predicting micrometastatic disease in cutaneous malignant melanoma. Br J Dermatol 146:832–835 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'PubMed', 'value': '2564228', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/2564228/'}]}
    2. Agrup P, Carstam R, Wittbjer A, Rorsman H, Rosengren E (1989) Tyrosinase activity in serum from patients with malignant melanoma. Acta Derm Venereol 69:120–124 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'PMC', 'value': 'PMC1602212', 'is_inner': False, 'url': 'https://pmc.ncbi.nlm.nih.gov/articles/PMC1602212/'}, {'type': 'PubMed', 'value': '14695333', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/14695333/'}]}
    2. Alonso SR, Ortiz P, Pollan M, Perez-Gomez B, Sanchez L, Acuna MJ, Pajares R, Martinez-Tello FJ, Hortelano CM, Piris MA, et al (2004) Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. Am J Pathol 164:193–203 - PMC - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1038/modpathol.3800151', 'is_inner': False, 'url': 'https://doi.org/10.1038/modpathol.3800151'}, {'type': 'PubMed', 'value': '15133476', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/15133476/'}]}
    2. Andersen K, Nesland JM, Holm R, Florenes VA, Fodstad O, Maelandsmo GM (2004) Expression of S100A4 combined with reduced E-cadherin expression predicts patient outcome in malignant melanoma. Mod Pathol 17:990–997 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1158/1078-0432.CCR-05-0011', 'is_inner': False, 'url': 'https://doi.org/10.1158/1078-0432.ccr-05-0011'}, {'type': 'PubMed', 'value': '16361544', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/16361544/'}]}
    2. Bachmann IM, Straume O, Puntervoll HE, Kalvenes MB, Akslen LA (2005) Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma. Clin Cancer Res 11:8606–8614 - PubMed

Publication types

MeSH terms

Substances